Latest ebit for NBIO: $-1.5M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2024
Trailing 12 months ending Sep 30, 2024
The latest EBIT for NBIO is $-1.5M as of September 2024. That compares with $-1.3M in the prior-year period — down 14.4% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Nascent Biotech's historical trend and sector peers before judging valuation or financial health.
Over the past year, NBIO's EBIT moved from $-1.3M to $-1.5M — a 14.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nascent Biotech's operating scale or balance-sheet position.
Against Healthcare companies, NBIO currently prints $-1.5M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Nascent Biotech's growth, margins, and balance sheet.
A EBIT figure of $-1.5M for NBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.
After noting NBIO's EBIT ($-1.5M), review year-over-year change from $-1.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.